Back to results
US 2003/0207273 A1Published application
Polynucleotide primers and probes for rapid detection of Group B streptococcal (GBS)
OwnerBetty Wu, Purnima Kurnoolinventors
Life of this patent
Estimating the term…
Abstract
Highly specific oligonucleotide primers and probes useful in a rapid and specific method for detecting the presence of Group B Streptococcal (GBS) or Streptococcus agalactiae infection in a biological sample.
Claims14
A method of testing for the presence of Streptococcus agalactiae, comprising:
- (a) contacting a nucleic acid sample suspected of being infected with Group B Streptococcal (GBS), with (i) a first pair of CAMP-based Group B Streptococcal (GBS)-specific primers, and (ii) a second pair of Sip-based GBS-specific primers, under conditions wherein GBS-related nucleic acids are amplified;
- and
- (b) detecting the presence of GBS-related nucleic acids.
A method of amplifying a nucleic acid related to Group B Streptococcal (GBS), comprising:
- (a) contacting a GB S-related target nucleic acid with (i) a first pair of CAMP-based Group B Streptococcal (GBS)-specific primers, (ii) a CAMP-based Group B Streptococcal (GB S)-specific probe, (iii) a second pair of Sip-based GBS-specific primers, and (iv) a Sip-based GBS-specific probe, under conditions wherein GBS-related nucleic acids are amplified;
- and
- (b) detecting the amplified product.
An in vitro method for detecting the presence of Streptococcus agalactiae in a biological sample, comprising:
- (a) releasing nucleic acids from said biological sample;
- (b) performing PCR in a total volume of between 0.2-100 μl in the presence of a first pair of primers comprising SEQ ID NOs:1 and 2, and a second pair of primers comprising SEQ ID NOs:4 and 5, and labeled probes comprising SEQ ID NOs:3 and 6, under conditions wherein the presence of a Streptococcus agalactiae-related nucleic acid sequence results in an amplified and labeled PCR product;
- and
- (c) detecting the presence of a labeled PCR product.
1 more element
A method detecting a Group B Streptococcal (GBS) infection in a patient, comprising:
- (a) obtaining a biological sample from the patient;
- (b) releasing nucleic acids from said biological sample;
- (c) performing PCR in a total volume of between 0.2-100 μl in the presence of a first pair of primers comprising SEQ ID NOs:1 and 2, and a second pair of primers comprising SEQ ID NOs:4 and 5, and labeled probes comprising SEQ ID NOs:3 and 6, under conditions wherein the presence of a Streptococcus agalactiae-related nucleic acid sequence results in an amplified and labeled PCR product;
- and
- (d) detecting the presence of a labeled PCR product, wherein the presence of a labeled PCR product indicates the presence of a GBS infection.
2 more elements
Dependencies are inferred from the claim text.